Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 57 clinical trials
HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation

Ultrasound surveillance for HCC has a wide ranging sensitivity, dependent on many factors such as operator experience, patient body habitus and liver parenchymal heterogeneity due to chronic liver disease and cirrhosis. In a select group of patients, surveillance ultrasound can be suboptimal or near non-diagnostic.

platelet count
cancer
hypertension
liver disease
liver ultrasound
  • 0 views
  • 19 Feb, 2024
A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects

This is a randomized, single-blind, placebo-controlled, once daily (QD) dose study of CRV431 in presumed NASH F2/F3 subjects.

fibroscan
fatty liver
fibrosis
vcte
hepatic fibrosis
  • 0 views
  • 19 Feb, 2024
Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function

Replacement of Tacrolimus by Everolimus may have a reduced incidence of renal dysfunction in liver transplant patients who already have chronic kidney disease or peri-operative acute kidney injury. Liver transplant patients receive potent induction immunosuppression in the form of rabbit anti thymocyte globulin.

immunosuppression
renal function
nephrotoxicity
renal failure
renal injury
  • 0 views
  • 19 Feb, 2024
Longitudinal Immune-phenotyping of HCC Following MK-3475

The sub-study is a tumour sample collection study which will provide pre-treatment immune microenvironment data from up to 15 pairs of HCC/adjuvant liver tissue samples. Translational analyses performed for liver tissue samples in the sub-study will be harmonized with the analyses on liver tissue samples collected in the main study.

hepatitis
oncolytic virus therapy
immunomodulator
blood transfusion
adjuvant
  • 0 views
  • 19 Feb, 2024
The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics

This is a prospective, single-center, open-label, single-dose, Phase 1 study, to assess the effect of moderate hepatic impairment due to liver cirrhosis on the pharmacokinetics of aprocitentan (ACT-132577).

renal function
ovarian failure
cirrhosis
kidney function tests
serum pregnancy test
  • 0 views
  • 19 Feb, 2024
Neo-TACE-HAIC for BCLC B Stage HCC (Neoconcept)

Hepatocellular carcinoma (HCC) patients is a common disease in the East Asia. Although BCLC (Barcelona clinical liver cancer) system recommend to transarterial chemoembolization (TACE) for BCLC B stage patients, increasing studies suggested that hepatic resection provided survival benefit for those patients.

cancer
oxaliplatin
fluorouracil
folfox regimen
chemoembolization
  • 0 views
  • 19 Feb, 2024
SBRT Versus Ablation for Perivascular Hepatocellular Carcinoma

This trial is a multi-center, phase III, randomized (1:1) clinical trial. The aim is to explore the efficacy and safety of SBRT for perivascular hepatocellular carcinoma, compared with RFA.

radiofrequency ablation
stereotactic body radiation therapy
hepatocellular carcinoma
recurrent hepatocellular carcinoma
carcinoma
  • 0 views
  • 19 Feb, 2024
Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma

This study aims to test the safety of hepatic artery infusion pump placement, a standard surgical procedure, and intraarterial chemotherapy initiation with the standard medication floxuridine (FUDR), using the Medtronic Synchromed II pump combined with the Codman arterial catheter in patients with unresectable (not removable by surgery) liver metastases from …

dexamethasone
metastasis
hepatitis c
adenocarcinoma
liver metastasis
  • 0 views
  • 19 Feb, 2024
Preliminary Antitumor Activity Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma

The primary objective of this study is to assess the preliminary antitumor activity as indicated by overall response rate (ORR) of tislelizumab in combination with lenvatinib in participants with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC).

cancer
unresectable hepatocellular carcinoma
carcinoma
lenvatinib
hepatocellular carcinoma
  • 0 views
  • 19 Feb, 2024
Bintrafusp Alfa in Previously Treated Patients With Recurrent and Metastatic (R/M) Non-keratinizing Nasopharyngeal Carcinoma (NPC)

This would be a phase II prospective single arm mono-institutional study conducted in Queen Mary Hospital (Hong Kong) assessing the efficacy and safety of bintrafusp alfa in previously treated patients with recurrent and metastatic (R/M) non-keratinizing nasopharyngeal carcinoma (NPC).

platelet count
immunomodulators
recurrent disease
serum aspartate aminotransferase
secondary malignant neoplasm of liver
  • 0 views
  • 19 Feb, 2024